RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Black Diamond Therapeutics Stock

Black Diamond Therapeutics ROA 2025

Black Diamond Therapeutics ROA

-0.52

Ticker

BDTX

ISIN

US09203E1055

WKN

A2PYWB

In 2025, Black Diamond Therapeutics's return on assets (ROA) was -0.52, a -10.87% increase from the -0.58 ROA in the previous year.

Black Diamond Therapeutics Aktienanalyse

What does Black Diamond Therapeutics do?

Black Diamond Therapeutics Inc. is a biopharmaceutical company specializing in the development of therapeutic solutions for specific types of cancer. It was founded in 2014 and is based in Cambridge, Massachusetts. The company utilizes a unique technology platform that combines protein engineering and big data. The founders, Elizabeth Buck and David Epstein, recognized the opportunity to address a problem in cancer therapy by utilizing innovative technology. They established Black Diamond Therapeutics to develop targeted therapies tailored to specific mutations in cancer-causing proteins using protein engineering technology. The company's business model is based on three pillars – the innovative use of big data, protein engineering technology, and close collaboration with the scientific community. Black Diamond Therapeutics specializes in treating cancers caused by rare mutations that have not responded well to conventional treatments. They have developed a range of novel therapies that are highly precise and have low toxicity. These therapeutic agents specifically target mutations in a protein called kinase, aiming to attack and destroy tumor cells. One of their products, BDTX-189, is currently being tested in phase I/II clinical trials. It is a specific inhibitor of mutations in the EGFR protein expressed in cancer cells and shows promise for patients who have not responded to other therapies. Black Diamond Therapeutics has various other products in their pipeline focusing on the treatment of lung, stomach, colorectal, ovarian, and other rare cancers. The company collaborates closely with leading medical and research institutions to expand their pipeline and identify new potential therapies. They have formed partnerships and collaborations with other companies in the biotech industry, including Roche, Gilead Sciences, and AstraZeneca, to drive their growth and development. Black Diamond Therapeutics has gained recognition from investors and the scientific community in recent years. Their unique technology and innovative business model have established them as a significant player in the biotech industry, offering promising developments in cancer therapy. Black Diamond Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Black Diamond Therapeutics's Return on Assets (ROA)

Black Diamond Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Black Diamond Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Black Diamond Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Black Diamond Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Black Diamond Therapeutics stock

What is the Return on Assets (ROA) of Black Diamond Therapeutics this year?

The Return on Assets (ROA) of Black Diamond Therapeutics is -0.52 undefined this year.

What was the ROA of Black Diamond Therapeutics compared to the previous year?

The ROA of Black Diamond Therapeutics has increased by -10.87% compared to the previous year.

What consequences do high ROA have for investors of Black Diamond Therapeutics?

A high ROA is advantageous for investors of Black Diamond Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Black Diamond Therapeutics?

A low ROA can be unfavorable for investors of Black Diamond Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Black Diamond Therapeutics affect the company?

An increase in ROA of Black Diamond Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Black Diamond Therapeutics impact the company?

A reduction in the ROA of Black Diamond Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Black Diamond Therapeutics?

Some factors that can influence the ROA of Black Diamond Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Black Diamond Therapeutics important for investors?

The ROA of Black Diamond Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Black Diamond Therapeutics take to improve ROA?

To improve ROA, Black Diamond Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Black Diamond Therapeutics pay?

Over the past 12 months, Black Diamond Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Black Diamond Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Black Diamond Therapeutics?

The current dividend yield of Black Diamond Therapeutics is .

When does Black Diamond Therapeutics pay dividends?

Black Diamond Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Black Diamond Therapeutics?

Black Diamond Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Black Diamond Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Black Diamond Therapeutics located?

Black Diamond Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Black Diamond Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Black Diamond Therapeutics from 3/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/6/2025.

When did Black Diamond Therapeutics pay the last dividend?

The last dividend was paid out on 3/6/2025.

What was the dividend of Black Diamond Therapeutics in the year 2024?

In the year 2024, Black Diamond Therapeutics distributed 0 USD as dividends.

In which currency does Black Diamond Therapeutics pay out the dividend?

The dividends of Black Diamond Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Black Diamond Therapeutics

Our stock analysis for Black Diamond Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Black Diamond Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.